
FDA Clears IND for Novel DLL3-Targeted ADC in Solid Tumors
The FDA has cleared the investigational new drug (IND) application for IDE849 (SHR-4849) in solid tumor treatment. IDE849 is a first-in-class delta-like ligand 3 (DLL3) topoisomerase-I (TOP1) antibody-drug conjugate (ADC). With this clearance, a phase 1 …